Telitacicept

{
  "id": "MLC-T-ONC-017054",
  "term": "Telitacicept",
  "field": "Oncology and biomedicine",
  "definition": "A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) fused to a human immunoglobulin (Ig) fragment crystallizable (Fc) domain, with potential immunomodulating activity. Upon administration, telitacicept targets both tumor necrosis factor ligand superfamily member 13B (TNFSF13B; BAFF; B lymphocyte stimulator; BLyS) and tumor necrosis factor ligand superfamily member 13 (TNFSF13; a proliferation-inducing ligand; APRIL) and inhibits their interaction with their cell membrane receptors, including TACI, tumor necrosis factor receptor superfamily member 17 (TNFRSF17; B-cell maturation antigen; BCMA) and tumor necrosis factor receptor superfamily member 13C (TNFRSF13C; BAFF receptor; BAFF-R). This inhibits B-cell proliferation and maturation, thereby inhibiting B-cell mediated autoimmune responses. APRIL and BAFF, and their interactions with their receptors TACI, BCMA and BAFF-R, play important roles in in B-cell proliferation and survival.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/telitacicept/"
}